Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Gary L. Heady"'
Autor:
Philip J. Ebert, Gary L. Heady, Bruce W. Konicek, Melinda D. Willard, Stephanie L. Stout, Julie Stewart, David E. Timm, Yi Zeng, Victoria L. Peek, Suzane L. Um, Isabella H. Wulur, Beverly L. Falcon, Andrew Capen, Kelly M. Credille, Yong Wang, Jennifer R. Stephens, Sau-Chi Betty Yan, Richard A. Walgren, Bharvin K. R. Patel
Publikováno v:
Oncotarget
Merestinib is an oral multi-kinase inhibitor targeting a limited number of oncokinases including MET, AXL, RON and MKNK1/2. Here, we report that merestinib inhibits neurotrophic receptor tyrosine kinases NTRK1/2/3 which are oncogenic drivers in tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7d248b4902618ce5f3d208e81ce69d6
https://doi.org/10.18632/oncotarget.24488
https://doi.org/10.18632/oncotarget.24488
Autor:
Sau-Chi Betty Yan, Kelly M. Credille, Suzane L. Um, John N. Calley, Victoria L. Peek, Jennifer R. Stephens, Andrew Capen, Yi Zeng, Philip J. Ebert, Steve M. Bray, Isabella H. Wulur, Melinda D. Willard, Richard A. Walgren, Bruce W. Konicek, Bharvin Kumar Patel, Gary L. Heady
Publikováno v:
Cancer Research. 76:2647-2647
In cancer, the formation of chimeric gene fusions by genomic rearrangement causes aberrant receptor tyrosine kinase activation resulting in sustained oncogenic signaling driving tumorigenesis. Neurotrophic tyrosine receptor kinase 1 (NTRK1), the cogn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eebed1fedf723cd14ff6aefa642780ca
https://doi.org/10.1158/1538-7445.am2016-2647
https://doi.org/10.1158/1538-7445.am2016-2647